

Curriculum Vitae

Daniel J. Morgan, Ph.D.

Current Position: Professor (with Tenure) and Chair, Department of
Biomedical Sciences
Idaho State University

Adjunct Associate Professor, Department of
Pharmaceutical Sciences, Marshall University

Adjunct Associate Professor, Department of
Neuroscience and Experimental Therapeutics
Penn State College of Medicine

Curriculum Vitae Date: July 1, 2026

Contact Information

Business Address: Department of Biomedical Sciences
Idaho State University
921 South 8th Avenue
Stop 8288
Pocatello, ID 83209

Business Phone: (732) 309-8281
E-mail: danielmorgan@isu.edu

Education

2027	M.B.A.	Business Administration, Marshall University (currently enrolled)
2004	Ph.D.	Neuroscience and Physiology, Rutgers University Thesis Title: "Developmental and Genetic Analysis of ProSAAS, A Putative PC1 Inhibitor in the Mouse"
1997	B.A.	Biology, Grinnell College

Post Graduate Education and Training

2007-2010	Post-Doctoral Fellow, Psychological and Brain Sciences, Indiana University
2004-2007	Senior Fellow, Pharmacology, University of Washington

1998-2004	Graduate Assistant and Post-Doctoral Fellow, Cell Biology and Neuroscience, Rutgers University
1996-1997	Summer Internship, Neuroscience, Iowa State University

Employment History

Academic Appointments

2024-present	Adjunct Associate Professor, Department of Pharmaceutical Sciences, Marshall University School of Pharmacy
2023-present	Adjunct Associate Professor, Department of Biology, Texas Tech University
2020-present	Adjunct Associate Professor, Department of Neural and Experimental Therapeutics, Penn State College of Medicine
2021-2025	Associate Professor (with Tenure) and Vice Chair, Department of Biomedical Sciences, Joan C Edwards School of Medicine at Marshall University
2020-2021	Associate Professor (with Tenure) and Associate Vice Chair, Department of Biomedical Sciences, Joan C Edwards School of Medicine at Marshall University
2020	Associate Professor (with Tenure), Department of Anesthesiology and Perioperative Medicine, Penn State College of Medicine Joint Appointments: Department of Neural & Behavioral Sciences and Pharmacology
2012-2020	Assistant Professor, Department of Anesthesiology and Perioperative Medicine, Penn State College of Medicine Joint Appointment: Department of Neural & Behavioral Sciences and Pharmacology
2010-2015	Research Scientist, Department of Psychological and Brain Sciences, Indiana University

Other Employment

1999-2004	Learning Specialist and Evening Supervisor, Rutgers University Learning Resource Center
-----------	---

Professional Society Membership

2020-2024	British Pharmacological Society
2016	International Association for the Study of Pain
2010-Present	American Society for Pharmacology and Experimental Therapeutics
2009-Present	International Cannabinoid Research Society
1999-Present	Society for Neuroscience

Honors and Awards

2024	Babson College Substance Use Disorder SPRINT program Travel Award
2017	Jackson Laboratories “Genetics of Addiction” Short Course Travel Award
2014	Cold Spring Harbor Laboratory “Cellular Biology of Addiction” Short Course Travel Award
2014	Winter Brain Travel Fellow Award
2013-2015	Satvir Tevethia Junior Faculty Research Scholar
2011	Julius Axelrod Symposium Travel Award
2010-2011	Indiana Academy of Science Senior Research Award
2010	Chicago Society for Neuroscience Postdoctoral Poster Award
2009	NIDA Early Career Investigator Award
2006	American Society for Cell Biology Travel Award
2000	UMDNJ Champions Scholarship
1993-1997	Grinnell College Trustee Honor Scholarship

Additional Training and Coursework

American Society for Pharmacology and Experimental Therapeutics Leadership Academy
American Society for Pharmacology and Experimental Therapeutics (ASPET) Online
June 2026-December 2026

Babson SPRINT Program for Entrepreneurship and Commercialization of Substance Use Disorder Treatments
Babson College and National Institute on Drug Abuse
Babson Park, MA
August 18 – 23, 2024

Leadership Education and Development (LEAD) Certificate Program
Association of American of Medical Colleges
Washington DC
March 2022 – March 2023

John Marshall Leadership Fellows Program
Center for Teaching and Learning
Marshall University, Huntington, WV
January – April 2021

Leadership Academy
Office of Faculty and Professional Development
Penn State University, University Park, PA
September 22 – 27, 2019

Genetics of Addiction Short Course
Jackson Laboratories
Bar Harbor, ME
September 10 – 15, 2017

Cellular Biology of Addiction Short Course
National Institute on Drug Abuse and Cold Spring Harbor Laboratory
Barcelona, Spain
July 13 – 20, 2014

Grants Academy
Office of Research Affairs
Penn State College of Medicine, Hershey, PA
September 2013 – April 2014

Junior Faculty Development Program
Office of Faculty and Professional Development
Penn State College of Medicine, Hershey PA
September 2013 – May 2014

Administrative Service

Institutional Service

Idaho State University

2026	Member, Pharmacy Practice and Administrative Science Department Faculty Search Committee
2025-present	Member, Biomedical Research Investing in Growth and ISU Talent (BRING-IT) Grant Steering Committee
2025-present	Member, Idaho State University College of Pharmacy and Health Professions Administrative Council

2025-present Member, Idaho State University College of Pharmacy and Health Professions Graduate Education and Research Committee

Marshall University

2024 Member, Department of Biomedical Sciences Addiction Faculty Search Committee

2023 Member, Joan C. Edwards School of Medicine Dean's Award for Excellence in Research Selection Committee

2023 Member, Joan C. Edwards School of Medicine Dean's Award for Excellence in Education Selection Committee

2022-2023 Member, Joan C. Edwards School of Medicine Mentoring Symposium Organizing Committee

2021-2025 Chair, Joan C. Edwards School of Medicine Visiting Scholar Seminar Series Committee

2021 Chair, Department of Biomedical Sciences Addiction Faculty Search Committee

2020-2025 Chair, Marshall University Addiction and Chronic Pain Research Center Planning Committee

Penn State College of Medicine

2019-2020 Member, Department of Anesthesiology and Perioperative Medicine Grand Rounds Committee

2019-2020 Member, Penn State College of Medicine Institutional Animal Use and Care Committee

2019-2020 Chair, Penn State Biomedical Sciences Graduate Program Seminar Committee

2018-2020 Member, Penn State Neuroscience Graduate Program Admissions Committee

2017-2018 Chair, Penn State University Graduate Council Committee on Committees and Procedures

2016-2018 Chair, Penn State University Graduate Exhibition Sub-Committee

2015-2020 Member, Penn State Biomedical Sciences Graduate Program Admissions Committee

2015-2020 Member, Department of Anesthesiology Resource Allocation Panel Committee

2015-2020 Member, Penn State University Graduate Council Committee on Graduate Student Awards and Fellowships

2015-2020 Member, Penn State College of Medicine Office of Research

	Development Grant Reviewer
2015-2016	Member, Penn State University Graduate Council Committee on Graduate Student and Faculty Issues
2014-2019	Member, Penn State Biomedical Sciences Graduate Program Seminar Committee
2014-2018	Member, Penn State University Graduate Council

National Service

2024-present	Member, ASPET Strengthening Divisions Task Force
2021-2025	Member, Symposium on Substance Use Research Organizing Committee
2021-2023	Secretary/Treasurer, ASPET Neuropharmacology Division
2020-2021	Chair, Sub-committee to Establish a Diversity Enhancement and Inclusion Career Achievement Award for the Neuropharmacology Division of ASPET
2018	Member, International Cannabinoid Research Society Program Committee
2017-present	Member, Winter Conference on Brain Research Program Committee
2016-2025	Member, ASPET Neuropharmacology Division Executive Committee
2016-2017	Member, Winter Conference on Brain Research Travel Award Committee

Grant Reviewer

2024	Panel Member, Congressionally Directed Medical Research Programs, Toxic Exposures Research Program (TERP)
2024	Israel Science Foundation (ISF)
2023-present	National Science Foundation (NSF)
2023 and 2026	West Virginia Clinical and Translational Science Institute
2019 and 2022	Canadian Institute of Health Research College of Reviewers
2019-2020	Florida Department of Health
2019	Panel Member, Congressionally Directed Medical Research Programs, Spinal Cord Injury Research Program (SCIRP)
2018	University of Buffalo Clinical and Translational Science Institute
2016	Health Research Council of New Zealand
2016	Prestige (France) Postdoctoral Research

2014 Austrian Science Fund

Manuscript Reviewer

2024-Present	Viewpoint Editor, <i>Journal of Pharmacology and Experimental Therapeutics</i>
2024-Present	Ad Hoc Reviewer, <i>Frontiers in Veterinary Sciences, Biomedicine and Pharmacotherapy, Cannabis and Cannabinoid Research</i>
2023-2024	Special Issue Associate Editor, <i>Journal of Pharmacology and Experimental Therapeutics</i>
2023-Present	Ad Hoc Reviewer, <i>Physiological Reports</i>
2023-Present	Ad Hoc Reviewer, <i>Biochemical Pharmacology</i>
2021-Present	Editorial Board, <i>Journal of Pharmacology and Experimental Therapeutics</i>
2020-2023	Editorial Board, <i>Pharmacology Research & Perspectives</i>
2020-Present	Editorial Board, <i>Frontiers in Molecular Neuroscience</i>
2019-Present	Ad Hoc Reviewer, <i>Journal of Pharmacology and Experimental Therapeutics</i>
2019-Present	Ad Hoc Reviewer, <i>International Union of Biochemistry and Molecular Biology Life</i>
2019-Present	Ad Hoc Reviewer, <i>Pharmacology, Biochemistry, and Behavior</i>
2019-Present	Ad Hoc Reviewer, <i>Neuroscience Letters</i>
2019-Present	Ad Hoc Reviewer, <i>European Journal of Pharmacology</i>
2019-Present	Ad Hoc Reviewer, <i>Pain</i>
2018-Present	Ad Hoc Reviewer, <i>ACS Chemical Neuroscience</i>
2018-Present	Ad Hoc Reviewer, <i>Acta Pharmacologica Sinica</i>
2018-Present	Ad Hoc Reviewer, <i>Current Neuropharmacology</i>
2018-Present	Ad Hoc Reviewer, <i>Drug and Alcohol Dependence</i>
2017-Present	Ad Hoc Reviewer, <i>British Journal of Pharmacology</i>
2017-Present	Ad Hoc Reviewer, <i>European Journal of Pain</i>
2017-Present	Ad Hoc Reviewer, <i>Neuropharmacology</i>
2017-Present	Ad Hoc Reviewer, <i>Scientific Reports</i>
2015-Present	Ad Hoc Reviewer, <i>European Journal of Clinical Psychopharmacology</i>
2014-2016	Special Issue Guest Editor and Reviewer, <i>Progress in</i>

	<i>Neuro-Psychopharmacology and Biological Psychiatry</i>
2013-Present	Ad Hoc Reviewer, <i>PLOS One</i>
2013-Present	Ad Hoc Reviewer, <i>European Journal of Pharmaceutical Sciences</i>
2011	Ad Hoc Reviewer, <i>Molecular and Cellular Endocrinology</i>

Teaching Service

Undergraduate Student Teaching

Indiana University

2010-2011	Lecturer, Pharmacology of Drug Addiction 30 attendees, 60 contact hours/year
2009-2011	Lecturer, Molecular Methods of Neuroscience Research 20 attendees, 6 contact hours/year

University of Washington

2006	Lecturer, Senior Seminar in Molecular, Cellular and Developmental Biology 20 attendees, 10 contact hours/year
------	--

Graduate Student Teaching

Idaho State University

2026- present	Course Director, PSCI 6603, Scientific Communication, 2 attendees, 23 contact hours
2026-present	Lecturer, PSCI 6653, Principles of Biopharmaceutical Analysis, 4 attendees, 3 contact hours

Marshall University

2023-2025	Lecturer, BSC 640, Cell Biology and Biotechnology 4 attendees, 4 contact hours/year
2022-2025	Course Director, BMS 813, Research in Biomedical Research 3 attendees, 5 contact hours/year
2021-2025	Course Director and Lecturer, BMR 650, Neurobiology of Addiction I 4 attendees, 24 contact hours/year

Penn State College of Medicine

2020	Lecturer, CMED 507, Techniques of Animal Experimentation 4 attendees, 1 contact hour/year
2019	Lecturer, ANAT 590, Professional Development Colloquium 7 attendees, 1 contact hour/year
2019-2020	Lecturer, BMS 506, Biological Basis of Human Health and Disease 12 attendees, 2 contact hours/year
2016	Lecturer, PHARM 520, Principles of Drug Action 10 attendees, 1 contact hour/year
2014-2020	Lecturer, NEU 521, Systems Neuroscience 5 attendees, 3 contact hours/year
2014-2019	Lecturer, PHARM 561, Neuropharmacology 2 attendees, 20 contact hours/year
2014-2015	Lecturer, BMS 597, Organizing Principles of Biomedical Sciences 30 attendees, 1 contact hours/year
2013-2019	Lecturer, NEU 520, Cellular and Molecular Neuroscience 5 attendees, 5 contact hours/year

Indiana University

2009	Lecturer, Neuro 501, Neural Science I 20 attendees, 10 contact hours/year
------	--

Pharmacy Student Teaching

2025-present	Instructor, PHAR 9924, Physicochemical Basis of Drug Action, 60 attendees, 4 contact hours/year
--------------	---

Medical Student Teaching

2024-2025	Instructor, MDC 801, Molecular and Cellular Foundations 75 attendees, 2 contact hours/year
2023	Instructor, MS2 Self-Directed Learning 6 attendees, 6 contact hours/year
2021- present	Instructor, MS1 and MS2 Clinical Reasoning 6 attendees, 12 contact hours/year

Mentorship Activities

Years of Mentorship	Name of Mentee	Position During Mentorship	Current Position
2026-present	Bret Hirshe	Undergraduate Summer Intern	Undergraduate, Brigham Young University-Idaho
2026-present	Sameena Mateen	Postdoctoral Fellow	Postdoc, Idaho State University
2025-present	Diana Cortez	Post-Bac Student	Post-Bac, Idaho State University
2022-present	Kayla DeSchepper	Predoctoral Student	Graduate Student, Marshall University
2024	Olivia McCoy	Medical Student	Medical Student, Marshall University
2024	Rebecca Hicks	Medical Student	Medical Student, Marshall University
2023	Kahleif Tye	High School Student	Student, Huntington High School
2022-2023	Malabika Maulik	Postdoctoral Fellow	Assistant Professor, Oklahoma State University
2021-2024	Courtney Lulek	Undergraduate Student	MD/PhD Student, Marshall University
2021-2022	Madison Michels	Undergraduate Student	Medical Student, WV School of Osteopathic Medicine
2019-2023	Lataijah Crawford	Predoctoral Student	Postdoc Fellow, NIH
2019-2022	Mary Piscura	Predoctoral Student	Assistant Professor, Edward Via College of Osteopathic Medicine
2018-2020	Peter Milianta	Medical Student	Resident Physician, Brown University
2017-2019	Bradley Nolan	Undergraduate Student	Graduate Student, Universitat Pompeu Fabra
2017	John Muller	Medical Student	Resident Physician, New York Univesity

2016-2019	David Hale	Medical Student	Neurology Fellow, John Hopkins University
2016-2020	Diana Castro	Post-Bac Student	Lab Technician, Penn State University
2016	Erin Ferguson	Undergraduate Student	Data Analyst, Cognito Therapeutics
2015-2017	Rebecca LaFleur	Postdoctoral Resident	Attending Veterinarian, Jackson Labs Bar Harbor, MA
2015	Nathan DeTurk	Medical Student	Resident Physician, University of Virginia
2014-2017	Matthew Yuill	Predoctoral Student	Scientist, Psychogenics
2014-2016	Aaron Kline	Undergraduate Student	Medical Supply, Ft. Worth, TX
2014	William Christie	Medical Student	Resident, University of Colorado
2013-2024	Angela Henderson- Redmond	Postdoctoral Fellow	Assistant Professor, Marshall University
2013-2018	Caitlin Nealon	Predoctoral Student	Museum Curator, San Jose, CA
2013-2014	Tammy Lowe	Undergraduate Student	Undergraduate, Benedict College
2013	Jeff Karduck	Medical Student	Assistant Professor, University of Iowa
2013	Xi Bei Tian	Anesthesiology Resident	Attending Physician, Island Hospital, Anacortes, WA
2012-2016	Michael Zee	Undergraduate Student	Graduate Student, Indiana University
2012	Maciej Gonek	Undergraduate Student	Program Manager, Healing Breakthrough Foundation
2011-2013	Chris Haskins	Undergraduate Student	Attending Physician,

			University of Pittsburgh Medical Center
2011-2012	Mary-Jeannette Andrews	Undergraduate Student	Resident Physician, Indiana University
2011-2012	Alex Cook	Undergraduate Student	Neuropsychologist
2010-2014	David Marcus	Post-Bac Student	Postdoc, University of Washington
2010	Randa Amin	Predoctoral Student	Veterinarian, Sarasota, FL

Graduate Student Thesis Committee Service

Member, Liliana Rodriguez, PhD, Idaho State University, Biomedical Sciences, 2029

Member, Alleyna Martes, PhD, Idaho State University, Psychology, 2029

Chair, Kayla DeSchepper, PhD, Marshall University, Biomedical Sciences, 2026

Member, Nathan Olszewski, PhD, Marshall University, Biomedical Sciences, 2026

Member, Mohan Vamsi Bhumaiahgari, MS, Marshall University, Pharmacy, 2026

Member, Reshma Madhanu, MS, Marshall University, Pharmacy, 2026

Member, Michael Leonardo, PhD, Marshall University, Biomedical Sciences, 2026

Member, Rohit Yakamura, MS, Marshall University, Pharmacy, 2025

Member, Erika Butcher, MS, Marshall University, Biology, 2025

Chair, Lataijah Crawford, PhD, Penn State University, Biomedical Sciences, 2023

Chair, Mary Piscura, PhD, Penn State University, Anatomy, 2022

Member, Emily Friebe, PhD, Penn State University, Biomedical Sciences, 2021

Member, Daniel Hass, PhD, Penn State University, Neuroscience, 2019

Chair, Caitlin Nealon, PhD, Penn State University, Biomedical Sciences, 2018

Chair, Matthew Yuill, PhD, Penn State University, Neuroscience, 2017

Member, Rebecca LaFleur, MS, Penn State University, Lab Animal Medicine, 2017

Grant Support

Active Grants

No Grant Number, Morgan (PI) 07/01/26-06/30/27
Idaho State University Proposal Readiness and Enhancement Program Grant
Idaho State University Grants Academy
The goal of this grant is to establish a yearlong Grant's Academy Program that meets monthly to cover topics related to writing a competitive NIH grant application.
Role: PI
Total Direct Costs: \$3,500

Pending Grants

R16 GM165172-01, Rorabaugh (PI) 7/01/26-08/30/30
NIH/NIGMS (Impact Score of 16)
Dissecting G Protein Versus β -Arrestin-Mediated CB1 Receptor Signaling Pathways Using a Phosphorylation-Deficient CB1 Receptor.
The goal of this R16 grant is to assess cannabinoid tolerance and CB1R-mediated signaling in a novel C-terminal tail phosphorylation-deficient mutant mouse line.
Role: Co-Investigator
Total Direct Costs: \$400,000

Completed Grants

5U54GM104942-09, Hodder (PI) 10/01/24-09/30/25
NIH/NIGMS
West Virginia Clinical and Translational Science Institute (WV-CTSI): A Statewide Organization Building Research Excellence and Engaging Communities to Improve Health.
The goal of this pilot grant from the WV-CTSI entitled, "Development of a Novel Medication for Cannabis Use Disorder", is to assess whether pharmacological inhibition of peroxiredoxin 6 (PRDX6) could be an effective target for treatment of cannabis use disorder.
Role: Co-Investigator
Total Direct Costs: \$29,267

R01 DA044999, Morgan (PI) 09/01/18-08/31/24
NIH/NIDA
Mechanisms of cannabinoid tolerance.
The goal of this study is to determine whether JNK-mediated Δ^9 -THC tolerance is mediated through direct phosphorylation of the CB₁ receptor.
Role: PI
Total Direct Costs: \$1,592,000

P20 GM103434-22, Rankin (PI) 09/01/22-08/31/24
NIH/NIGMS

West Virginia IDeA Network of Biomedical Research Excellence (WV-INBRE).
The goal of this pilot grant from the WV-INBRE entitled, "*Role of proSAAS in Metabolic Disease*", is to investigate whether mutant mice lacking the neuropeptide proSAAS are resistant to high-fat diet-induced obesity.

Role: Co-Investigator

Total Direct Costs: \$60,000

R21 DE028650, Hu (PI)

04/01/18-03/31/20

NIH/NIDCR

The role of chronic cannabis and its two major psychoactive ingredients in papillomavirus-associated oropharyngeal disease.

The goal of this study was to determine whether Δ^9 -THC, cannabidiol, or inhaled cannabis enhance papillomavirus virulence in oropharyngeal disease.

Role: Co-investigator

Total Direct Costs: \$275,000

SAP#4100079742, Morgan (PI)

07/01/18-06/30/19

PA State Dept. of Health CURE Tobacco Settlement Funds

Agonist-specific mechanisms of cannabinoid tolerance.

The goal of this project was to provide Bridge funding for the re-submission of 1R01 DA044999.

Role: PI

Total Direct Costs: \$100,000

K01 DA037355, Morgan (PI)

02/01/15-01/31/18

NIH/NIDA

Desensitization and downregulation of CB1 during cannabinoid tolerance.

The goal of this study was to determine whether desensitization of downregulation of CB1 is responsible for JNK-mediated Δ^9 -THC tolerance.

Role: PI

Total Direct Costs: \$450,000

R21 DA036385, Morgan (PI)

07/15/13-06/30/16

NIH/NIDA

Characterization of a novel JNK-mediated mechanism of cannabinoid tolerance.

The goal of this study is to determine the form of JNK responsible for mediating tolerance to Δ^9 -THC and to identify transcriptional targets of JNK responsible for this process.

Role: PI

Total Direct Costs: \$250,000

SAP #4100057673, Morgan (PI)

07/15/13-12/31/15

PA State Dept. of Health CURE Tobacco Settlement Funds

Does enhanced cannabinoid receptor 1 (CB1) signaling increase the risk of drug abuse?

The goal of this study is to determine whether reward and dependence for

alcohol and morphine are increased in mice with enhanced cannabinoid signaling.

Role: PI

Total Direct Costs: \$200,000

No Grant Number, Morgan (PI)

07/01/14-06/30/15

Junior Faculty Development Program Research Support Grant

Desensitization and downregulation of CB1 during cannabinoid tolerance

The purpose of this grant was to purchase equipment needed for assessing CB1R neuroadaptations involved in cannabinoid tolerance.

Role: PI

Total Direct Costs: \$5000

No Grant Number, Morgan (PI)

07/01/14-06/30/15

Penn State Department of Anesthesiology Research Pilot grant

Does a "humanized" A118G potentiate alcohol consumption and reward in mice?

The goal of this study was to assess alcohol drinking behavior and reward in mutant mice expressing the A118G mu opioid receptor (MOR) polymorphism.

Role: PI

Total Direct Costs: 10,975

T32 HL007312, (Swartz, PI)

07/01/05-09/30/07

NIH/NHLBI

Experimental Pathology of Cardiovascular Disease

The goal of this training grant was to provide training for graduate students and postdoctoral fellows at the University of Washington School of Medicine doing cardiovascular research.

Role: Postdoctoral Fellow

T32 MH019957 (Pintar, PI)

06/01/03-5/31/04

NIH/NIMH

Molecular and Developmental Basis of Mental Illness

The goal of this training grant was to provide training for graduate students at Rutgers University doing neuroscience research relevant to mental illness.

Role: Graduate Student

R25 GM055145 (Leibowitz, PI)

08/01/97-07/30/99

NIH/NIGMS

Rutgers Initiative for Student Development (IMSD) Pipeline Program

The goal of this training grant was to increase the training and graduation of underrepresented (UR) PhD biomedical scientists.

Role: Graduate Student

Publications

Peer-reviewed Journal Articles (Trainees in Underline)

1. **Morgan, D.J.** Levi R., Wood, S.K., and Greenwood-Van Meerveld, B., Celebrating 50 unique Viewpoint perspectives in the Journal of Pharmacology and Experimental Therapeutics. *Journal of Pharmacology and Experimental Therapeutics*. **392(8)**:103646
2. Fricker, L.D., Fakira, A.K., Bobeck, E.N., Raddatz, M., Kim, K., DeSchepper, K.D., **Morgan, D.J.** ProSAAS neuropeptides and receptors GPR171 and GPR83: Potential therapeutic applications for pain, anxiety, and immunomodulation. *Journal of Pharmacology and Experimental Therapeutics*. **392(6)**:103599.
3. Brendle, S.A., Li, J., Sun, D., Zhu, J., Henderson-Redmond, A.N., **Morgan, D.J.**, Balogh, K.K., Covington, D., Shearer, D.A., and Hu, J. Intraperitoneal delivery of cannabidiol (CBD) and Δ^9 -tetrahydrocannabinol (THC) promotes papillomavirus infections in athymic nude mice. *Tumor Virus Research*. **19**: 200307.
4. Rorabaugh, R.B. and **Morgan, D.J.** CB1 Receptor Couples to Extracellular Regulated Kinase via Multiple Gai/o Isoforms. *Neuroreport*. **36(4)**:191-195.
5. Guindon, J., and **Morgan, D.J.** (2024). Special Section on Cannabinoid Signaling in Human Health and Disease-Editorial. *Journal of Pharmacology and Experimental Therapeutics*. **391(2)**:152-153.
6. Carr, J.A. and **Morgan, D.J.** (2024). Methocinnamox is a potent and long-acting antagonist that can prevent and reverse opioid-induced respiratory depression (Invited Viewpoint). *Journal of Pharmacology and Experimental Therapeutics*. **391(1)**:1-3
7. Barnes, R.C., Blanton, B., Dancel, C.L., Castro-Piedras, I. Rorabaugh, B.R., **Morgan, D.J.**, and Guindon J.G. (2024). Chronic administration of cannabinoid agonists ACEA (CB1), AM1241 (CB2), and CP55,940 (mixed CB1/CB2) induce sex-specific differences in tolerance and sex hormone changes in a chemotherapy-induced peripheral neuropathy. *Journal of Pharmacology and Experimental Therapeutics*. **391(2)**: 258-271
8. Barnes, R.C., Banjara, S., McHann, M.C., Almodovar, S., Henderson-Redmond, A.N., **Morgan, D.J.**, Castro-Piedras, I., Guindon J.G. (2024). Cannabidiol and amitriptyline exert dose and sex dependent antinociceptive effects, alone and in combination, that are partially mediated by serotonin 1A receptors. *Journal of Pharmacology and Experimental Therapeutics*. **388 (2)**: 655-669.
9. Rorabaugh, B.R., Guindon, J., **Morgan, D.J.** (2023). Role of cannabinoid signaling in cardiovascular function and ischemic injury. *Journal of Pharmacology and Experimental Therapeutics*. **387(3)**: 265-276.

10. Maulik, M., Looschen, K., Smith, C., Johnson, K., Carman, A., Nagisetty, C., Corriveau, K., DeSchepper, K., Michels, M., Henderson-Redmond, A.N., **Morgan, D.J.**, Mitra, S. (2023). Postpartum scarcity-adversity inflicts sex-specific cerebellar adaptations and reward behaviors in adolescence. *Pharmacology, Biochemistry, and Behavior*. **231**:173620.
11. Lulek, C., Maulik, M., Mitra, S., Guindon, J., **Morgan, D.J.**, Henderson-Redmond, A.N. (2023). Sex-differences in acute delta-9-tetrahydrocannabinol (Δ^9 -THC) response and tolerance as a function of mouse strain. *Psychopharmacology*. **240 (9)**: 1987-2003.
12. Piscura, M.K., Henderson-Redmond, A.N., Barnes, R.C., Mitra, S., Guindon, J., **Morgan, D.J.** (2023). Mechanisms of Cannabinoid Tolerance. *Biochemical Pharmacology*. **214**:115665.
13. Piscura, M.P., Sepulveda, D.E., Maulik, M., Guindon, J., Henderson-Redmond, A.N., **Morgan, D.J.** (2023). Cannabinoid tolerance in S426A/S430A x beta-arrestin2 double mutant mice. *Journal of Pharmacology and Experimental Therapeutics*. **385(1)**:17-34.
14. Crawford, L.C., Kim S.Y., Karelia, D., Sepulveda, D.E., **Morgan, D.J.**, Lu, J., Henderson-Redmond, A.N. (2022). Antinociceptive effects of Decursinol in mice with cisplatin-evoked neuropathic pain. *Frontiers in Pharmacology*. **13**: 968976
15. Aryal, D.K., Rodriguez, R.M., Nguyen, N.L., Pease, M.W., **Morgan, D.J.**, Pintar, J.E., Fricker, L.D., Wetsel, W.C. (2022). Mice lacking proSAAS display alterations in emotion, metabolism, and circadian entrainment. *Genes, Brain, and Behavior*. **21(7)**: e12827.
16. Henderson-Redmond, A.N., Sepulveda, D.E., Ferguson, E.L., Kline, A.M., Piscura, M.K., **Morgan, D.J.** (2022). Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9 tetrahydrocannabinol (Δ^9 -THC). *Psychopharmacology*. **239(5)**:1289-1309
17. Henderson-Redmond, A.N., Crawford, L.C., Sepulveda, D.E., Hale, D.E., Lesperance, J.J., **Morgan, D.J.** (2021). Sex differences in tolerance to delta-9-tetrahydrocannabinol (Δ^9 -THC) in mice with cisplatin-evoked chronic neuropathic pain. *Frontiers in Biomedical Sciences*. **8**: 684115
18. Stauch, C.M., Ammerman, B., Aynardi M.C., Sepulveda, D., Garner, M.R., Lewis, G., **Morgan, D.J.**, and Dhawan, A. (2021). Biomechanical effects of delta-9-tetrahydrocannabinol and cannabidiol, the major constituents of cannabis, in a Sprague Dawley rat Achilles tendon surgical repair model- A pilot study. *The Journal of American Sports Medicine*. **49(9)**: 2522–2527

19. Henderson-Redmond, A.N., Nealon, C.M., Davis, B.J., Yuill, M.B., Sepulveda, D.E., Blanton, H., Piscura, M.K., Zee, M.L., Haskins, C.P., Marcus, D.J., Mackie, K., Guindon, J., and **Morgan, D.J.** (2020). c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner. *Neuropharmacology*. **164**: 107847.
20. Blanton, H.L., Breslford, J., DeTurk, N., Pruitt, K., Narasimhan, M., **Morgan, D.J.**, and Guindon, J. (2019). Cannabinoids: current and future options to treat chronic pain. *Drugs*. **79**: 969-995.
21. Nealon, C.M., Henderson-Redmond, A.N., Hale, D.E., and **Morgan, D.J.** (2019). Tolerance to WIN55,212-2 is significantly delayed in desensitization-resistant S426A/S430A mice. *Neuropharmacology*. **148**:151-159.
22. Raup-Konsavage, W.M., Johnson, M., Legare, C.A., Yochum, G.S., **Morgan, D.J.**, and Vrana, K.E. (2018). Synthetic cannabinoid activity against colorectal cancer cells. *Cannabis and Cannabinoid Research*. **3**: 272-281.
23. LaFleur, R.A., Wilson, R.P., **Morgan D.J.**, Henderson-Redmond, A.N. (2018). Sex differences in the development of tolerance to delta-9-tetrahydrocannabinol (Δ^9 -THC) and CP55,940 in a mouse model of inflammatory pain. *Neuroreport*. **29**: 447-52.
24. Henderson-Redmond, A.N., Lowe, T., Tian, X.B., Zee, M.L., and **Morgan, D.J.** (2018). Sex-specific mechanisms of increased alcohol drinking in “humanized” A118G mutant mice. *Brain Research Bulletin*. **138**: 12-19.
25. Nealon, C.M., Patel, C., Worley, B.L., Henderson-Redmond, A.N., **Morgan, D.J.**, and Czyzyk, T.A. (2018). Alterations in nociception and morphine antinociception in mice fed a high-fat diet. *Brain Research Bulletin*. **138**: 64-72.
26. Berezniuk, I., Rodriguez, R.M., Zee, M.L., Marcus, D.J., Pintar, J.E., **Morgan, D.J.**, Wetsel, W.C., Fricker, L.D. (2017). ProSAAS-derived peptides are regulated by cocaine and are required for sensitization to the locomotor effects of cocaine. *Journal of Neurochemistry*. **143** (3): 268-81.
27. Yuill, M.B., Hale, D., Guindon J., **Morgan D.J.** (2017). Anti-nociceptive interactions between opioids and a cannabinoid receptor 2 agonist in inflammatory pain. *Molecular Pain*. **13**: 1-15.
28. Miller, S, Hu, SS, Leishman, E, **Morgan, D**, Wager-Miller, J, Bradshaw, HB, and Straiker, A. (2017). A GPR119 signaling system in the murine eye regulates intraocular pressure in a sex-dependent manner. *Investigative Ophthalmology and Visual Science*. **58** (7): 2930-38.

29. Marcus, D.J., Henderson-Redmond, A.N., Zee, M.L., Amin, R., Farnsworth, J.C., Andrews, M.J., Davis, B.J., Mackie, K., and **Morgan, D.J.** (2017). Mice expressing a “hyper-sensitive” form of the cannabinoid receptor 1 (CB1) show modestly alcohol preference and consumption. *PLOS One*. **12** (4): e0174826.
30. Marcus, D.J., Zee, M.L., Davis, B.J., Haskins, C.P., Andrews, M.J., Amin, R., Henderson-Redmond, A.N., Mackie, K., Czyzyk, T.A., **Morgan D.J.** (2016). Mice expressing a “hyper-sensitive” form of the cannabinoid receptor 1 (CB1) are not obese or diabetic. *PLOS One*. **11** (8): e0160462.
31. Yuill, M.B., Zee, M.L., Marcus, D.J., **Morgan D.J.** (2016). Tolerance to the anti-nociceptive and hypothermic effects of morphine are mediated by multiple isoforms of c-Jun N-terminal Kinase. *Neuroreport*. **27**: 392-6.
32. Van Bockstaele, E.J., **Morgan, D.J.**, and Richardson, H. (2016). New progress in understanding the molecular, cellular, and genetic basis of alcohol and poly-substance abuse. *Progress in Neuro-psychopharmacology and Biological Psychiatry*. **65**: 225-7.
33. Henderson-Redmond, A.N., Guindon, J, **Morgan DJ**. (2016). Roles for the endocannabinoid system in ethanol-motivated behavior. *Progress in Neuro-psychopharmacology and Biological Psychiatry*. **65**: 330-9.
34. Henderson-Redmond, A.N., Yuill, M.B., Lowe, T., Kline, A.M., Zee, M.L., Guindon, J., and **Morgan, D.J.** (2016). Morphine-induced anti-nociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. *Brain Research Bulletin*. **123**: 5-12.
35. Marcus, D.J., Zee, M.L., Hughes, A., Mackie, K., Hohmann, A.H., Guindon, J., and **Morgan, D.J.** (2015). Chronic tolerance to the analgesic effects of morphine requires c-Jun N-terminal kinase. *Molecular Pain*. **11**: 34.
36. **Morgan D.J.**, Davis, B.J., Kearn, C.S., Marcus, D.J., Cook, A.J., Wager-Miller, J., Straiker, A.S., Myoga, M.H., Stuart, J., Sim-Selley L.J., Czyzyk, T.A., Bradshaw, H.B., Selley, D.A., Mackie, K. (2014). Mutation of putative GRK phosphorylation sites in the cannabinoid receptor 1 (CB1) confers resistance to cannabinoid tolerance and hypersensitivity to cannabinoids in mice. *Journal of Neuroscience*. **34**: 5152-63.
37. Wu, CS., **Morgan, D.J.**,* Jew, C.P., Haskins, C.P., Andrews, M.J., Spencer, C, Czyzyk, T.A., Bradshaw, H.B., and Mackie, K. (2014). Long-term consequences of perinatal fatty acid amino hydrolase inhibition. *British Journal of Pharmacology*. **171**: 1420-34. (*authors contributed equally).

38. **Morgan, D.J.**, Muller, C.H., Murataeva, N., Davis, B.J., Mackie, K. (2012). Delta-9-Tetrahydrocannabinol (Δ^9 -THC) attenuates bicarbonate-stimulated motility and male fecundity. *British Journal of Pharmacology*. **165**: 2575-83.
39. Atkins, N., Mitchell, J., Romanova, R., **Morgan, D.J.**, Cominski, T., Ecker, J., Pintar, J.E., Sweedler, J., Gillete, M.U. (2010). Circadian integration of glutamatergic signals by little SAAS in novel suprachiasmatic circuits. *PLOS One*. **5**: e12612.
40. **Morgan, D.J.**, Wei, S. Mzhavia, N., Czyzyk, T.A., Mzhavia, N., Pan, H., Devi, L.A., Fricker, L.D., Pintar, J.E. (2010). The propeptide precursor proSAAS is involved in fetal neuropeptide processing and body weight regulation. *Journal of Neurochemistry*. **113**: 1275-1284.
41. **Morgan, D.J.**, Weisenhaus, M., Shum, S., Su, T., Zheng, R., Zhang C., Shokat, K.M., Hille, B., Babcock, D.F., and McKnight, G.S. (2007). A chemical-genetic approach to the study of PKA in specific tissues: Analysis of sperm capacitation. *Proceedings of the National Academy of Sciences*. **104**: 20740-20745.
42. **Morgan, D.J.**, Mzhavia, N., Peng, B., Pan, H., Devi, L.A. and Pintar, J.E. (2005). Embryonic gene expression and pro-protein processing of the putative PC1 inhibitor, proSAAS, during rodent development. *Journal of Neurochemistry*. **93**: 1454-62.
43. Czyzyk, T.A.*, **Morgan, D.J.***, Peng, B., Zhang, J., Karantzas, A., Arai, M., and Pintar, J.E. (2003). Targeted mutagenesis or processing enzymes and regulators: Implications for development and physiology. *Journal of Neuroscience Research*. **74**: 446-55. (*authors contributed equally)
44. Lei, Y., Xin, X., **Morgan, D.**, Pintar, J., and L. Fricker. (1999). Identification of mouse CPX-1, a novel member of metallocarboxypeptidase gene family with highest similarity to CPX-2. *DNA and Cell Biology*. **18**: 175-185.
45. Schuller, A., King, M., Zhang, J., Bolan, E., Pan, X., **Morgan, D.J.**, Chang, A., Czick, M., Unterwald, E., Pasternak, G., and Pintar, J.E. (1999). Retention of heroin and morphine-6 β -glucuronide analgesia in MOR-1 exon 1 knockout mice insensitive to morphine: Evidence for a novel MOR-1 related receptor. *Nature Neuroscience*. **2**: 151-156.

Book Chapters

1. Gordin, V., **Morgan, D.J.**, Mueller, M., Guevara, A., and Gordin, Y. (2019). Novel Analgesics. In T.R. Deer (Ed.), *Comprehensive Treatment of Chronic Pain by Medical, Interventional, and Integrative Approaches*. New York, NY: Springer.

2. Blanton, H.L., Bergeson, S.E., **Morgan, D.J.**, and Guindon, J. (2019). Alcohol and Pain Interactions. In V. Preedy (Ed.), *The Neuroscience of Alcohol: Mechanisms of Treatment*. New York, NY: Elsevier.

Textbooks

1. **Morgan, D.J.** *Therapeutic Uses and Liabilities for Cannabinoids in the Treatment of Chronic Pain*. Boca Raton, FL: Routledge Publishing and CRC Press. In preparation for 2026.

* Undergraduate, Graduate Student, and Postdoctoral Trainees Underlined

Lectures by Invitation (number continuously through each subsection)

Local

1. **Morgan, D.J.** Therapeutic uses and neuropsychiatric liabilities for cannabinoids in the treatment of chronic pain, Huntington, WV, Marshall University, February 23, 2024.
2. **Morgan, D.J.** Therapeutic uses and neuropsychiatric liabilities for cannabinoids in the treatment of chronic pain, Huntington, WV, Marshall University, April 21, 2023.
3. **Morgan, D.J.** Therapeutic uses and neuropsychiatric liabilities for cannabinoids in the treatment of chronic pain, Danville, PA, Geisinger Commonwealth School of Medicine, March 9, 2020.
4. **Morgan, D.J.** Therapeutic uses and neuropsychiatric liabilities for cannabinoids in the treatment of chronic pain, State College, PA, Committee for Substance Abuse Prevention Annual Meeting, October 8, 2019.
5. **Morgan, D.J.** Sex differences in cannabinoid response and tolerance, Penn State University, 4th Annual Addiction Symposium, Hershey, PA, November 28, 2018.
6. **Morgan, D.J.** Science on Tap: Medical Marijuana, Penn State University, State College, PA, June 21, 2018.
7. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Penn State University, Neural and Behavioral Sciences, Hershey, PA, April 26, 2018.
8. **Morgan, D.J.** Therapeutic use of cannabinoids for chronic pain, Penn State University, Opioid Summit, State College, PA, January 12, 2018.
9. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Penn State University, Pharmacology, Hershey, PA, November 9, 2017.

10. **Morgan, D.J.** Mechanisms of agonist-specific cannabinoid tolerance, Penn State University, Addiction Symposium, Hershey, PA, April 4, 2017.
11. **Morgan, D.J.** Novel mechanisms of Δ^9 -THC tolerance, Penn State University, Addiction Symposium, Hershey, PA, January 16, 2015.
12. **Morgan, D.J.** Therapeutic uses and limitations for cannabinoids in treating pain: lessons from preclinical rodent models, Penn State University, Research Quality Assurance, Hershey, PA, January 14, 2015.
13. **Morgan, D.J.** Therapeutic uses and limitations for cannabinoids in treating pain: lessons from preclinical rodent models, Penn State University, Anesthesiology Grand Rounds, Hershey, PA, May 24, 2014.
14. **Morgan, D.J.** Mutation of CB₁ desensitization sites: Implications for Δ^9 -THC tolerance, addiction, and metabolism, Penn State University, Cellular and Molecular Physiology, Hershey, PA, September 13, 2013.
15. **Morgan, D.J.** Coordinated inhibition of GRK and JNK signaling prevents tolerance for the analgesic effects of Δ^9 -THC, Penn State University, Anesthesiology, Hershey, PA, December 15, 2011.

National

16. **Morgan, D.J.** Cannabinoid signaling in human health and disease. Des Moines, IA, Des Moines University, May 21, 2025.
17. **Morgan, D.J.** Leadership, mentoring, and research development vision for the Department of Biomedical and Pharmaceutical Sciences. Pocatello, ID, Idaho State University, May 15, 2025.
18. **Morgan, D.J.** Cannabinoid signaling in human health and disease. Amarillo, TX, Texas Tech University School of Veterinary Medicine, December 2, 2024.
19. **Morgan, D.J.** Cannabinoid signaling in human health and disease. Rolla, MO, Missouri Science & Technology University, November 11, 2024.
20. **Morgan, D.J.** Cannabinoid signaling in human health and disease. Macon, GA, Mercer University School of Medicine, October 29, 2024.
21. **Morgan, D.J.** Strategic plan for implementation of a Molecular Bioscience PhD program. Chicago, IL, Roosevelt University, June 27, 2024.
22. **Morgan, D.J.** Therapeutic uses and neuropsychiatric liabilities for cannabinoids in the treatment of chronic pain, Lubbock, TX, Texas Tech University, October 26, 2023.

23. **Morgan, D.J.** The role of proSAAS in metabolic homeostasis, Winter Conference on Brain Research, Snowbird, UT, January 23, 2023.
24. **Morgan, D.J.** Sex Differences in Cannabinoid Signaling, Winter Conference on Brain Research, Big Sky, MT, January 30, 2020.
25. **Morgan, D.J.** Therapeutic uses and neuropsychiatric liabilities for cannabinoids in the treatment of chronic pain, Wernersville, PA, 4th Annual Caron Addiction Research Symposium, October 25, 2019.
26. **Morgan, D.J.** Mechanisms of Cannabinoid Tolerance, Marshall University, Huntington, WV, May 31, 2019.
27. **Morgan, D.J.** Mechanisms of Cannabinoid Tolerance, University of Florida College of Veterinary Medicine, Gainesville, FL, February 19, 2019.
28. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, University of Connecticut, Storrs, CT, July 31, 2017.
29. **Morgan, D.J.** Comparing “traditional” gene targeting/knock-out methods to CRISPR/Cas9, Winter Conference on Brain Research, Big Sky, MT, January 31, 2017.
30. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Carolina Cannabinoid Collaborative Conference, Philadelphia, PA, October 29, 2016.
31. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Virginia Commonwealth University, Richmond, VA, September 6, 2016.
32. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Creighton University School of Medicine, Omaha, NE, April 7, 2016.
33. **Morgan, D.J.** Co-chair symposium on Cannabinoid Signaling in Pain and Addiction: Translating Preclinical Basic Research to the Clinic, American Society for Pharmacology and Experimental Therapeutics, San Diego, CA, April 3, 2016.
34. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Texas Tech University, Lubbock, TX, March 29, 2016.
35. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Texas Tech University Health Sciences Center, Lubbock, TX, November 10, 2015.
36. **Morgan, D.J.** Deletion of proSAAS abolishes cocaine sensitization and increases anxiety-like behavior under highly aversive conditions, Winter Conference on Brain Research, Steamboat Springs, CO, January 27, 2014.

37. **Morgan, D.J.** Mutation of CB₁ desensitization sites: Implications for Δ^9 -THC tolerance, addiction, and metabolism, Temple University, Philadelphia, PA, November 19, 2013.
38. **Morgan, D.J.** Characterization of a novel c-Jun N-terminal kinase (JNK)-mediated mechanism of cannabinoid tolerance, Cannabinoids in the CNS Gordon Research Seminar, Waterville Valley, NH, August 3, 2013.
39. **Morgan, D.J.** Coordinated inhibition of GRK and JNK signaling prevents tolerance for the analgesic effects of Δ^9 -THC, Mayo Clinic Arizona, Scottsdale, AZ, February 2, 2012.
40. **Morgan, D.J.** Prolonging the High: Mutation of Cannabinoid Receptor Phosphorylation Sites Enhances the Magnitude and Duration of Cannabinoid Behaviors, Drake University, Des Moines, IA, February 25, 2010.
41. **Morgan, D.J.** Uncovering the mysteries of proSAAS: Implications for body weight regulation, drug addiction, and pro-protein processing, DePauw University, Greencastle, IN, March 10, 2009.
42. **Morgan, D.J.** Using Chemical-Genetics to Reversibly Inhibit Protein Kinase A: Implications for Male Reproduction, Future of Male Contraception Meeting, Seattle, WA, September 27, 2007.
43. **Morgan, D.J.** Using a Chemical Genetic Mutation in Protein Kinase A (PKA) as a Novel Tool to Investigate Male Fertility, Cincinnati Children's Hospital, Cincinnati, OH, February 8, 2007.
44. **Morgan, D.J.** Developmental and genetic analysis of proSAAS, a putative PC1 inhibitor in the mouse, University of California at San Francisco, San Francisco, CA, April 15, 2004.
45. **Morgan, D.J.** Developmental and genetic analysis of proSAAS, a putative PC1 inhibitor in the mouse, The Jackson Laboratories, Bar Harbor, ME, April 8, 2004.
46. **Morgan, D.J.** Developmental and genetic analysis of proSAAS, a putative PC1 inhibitor in the mouse, University of Washington, Seattle, WA, February 10, 2004.

International

47. **Morgan, D.J.** Mutant mice expressing an internalization-resistant form of CB₁R display enhanced cannabinoid tolerance, International Cannabinoid Research Society, Toronto, Canada, 2023.

48. **Morgan, D.J.** Mutant mice expressing an internalization-resistant form of CB₁R display enhanced cannabinoid tolerance, British Pharmacology Society, Liverpool, United Kingdom, 2022.
49. **Morgan, D.J.** Mechanisms of agonist-specific cannabinoid tolerance, International Cannabinoid Research Society, Leiden, Netherlands, 2018.
50. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, Winter Conference on Brain Research, Whistler, BC, Canada, 2018.
51. **Morgan, D.J.** Mechanisms of tolerance to Δ^9 -THC in rodent models of pathological pain, International Cannabinoid Research Society, Bukovina, Poland, 2016.
52. **Morgan, D.J.** Mechanisms of cannabinoid tolerance, CSHL/NIDA Cellular Biology of Addiction, Barcelona, Spain, 2014.